Literature DB >> 18849804

The use of the Wittmann Patch facilitates a high rate of fascial closure in severely injured trauma patients and critically ill emergency surgery patients.

Brandon H Tieu1, S David Cho, Nick Luem, Gordon Riha, John Mayberry, Martin A Schreiber.   

Abstract

BACKGROUND: The open abdomen after severe intra-abdominal trauma and emergency surgery is a major operative challenge. It is associated with high morbidity and prolonged hospital stays. Several management strategies have been developed to assist with fascial closure but no single method has emerged as the best. The Wittmann Patch (Starsurgical, Burlington, WI) is a unique device which uses velcro to permit progressive abdominal closure without necessitating serial operations. The purpose of this study was to determine the fascial closure rate using the Wittmann patch. We hypothesized that use of the patch would result in a high closure rate.
METHODS: Hospital billing codes were reviewed to identify those patients who underwent Wittmann patch placement. During the period from June 2002 to May of 2006, 29 patients were identified. These included 19 trauma patients and 10 other surgical patients. Other patients included vascular, bariatric, and emergency general surgery patients. The trauma registry and the patients' medical records were reviewed to determine injury severity, Acute Physiology and Chronic Health Evaluation II scores, fluid requirements, patch placement, management, and patient outcomes.
RESULTS: Twenty-two (76%) of the 29 patients survived to discharge. The average Acute Physiology and Chronic Health Evaluation II score was 25 +/- 6 in all patients, 22.9 +/- 6 in survivors, and 31 +/- 3 in those who died (p = 0.004). Mean injury severity scale and abdominal abbreviated injury scale scores in trauma patients were 28 +/- 10 and 3 +/- 2, respectively. The mean volume of fluid given during the 24 hours before having an open abdomen or patch placement was 17.6 L +/- 10.1 L. Twenty-five (86.2%) of 29 patients had at least one abdominal operation before placement of the patch (mean 1.3 +/- 1.0). Eighteen (82%) of 22 patients who survived to discharge had successful facial closure. Three patients (14%) required mesh placement for abdominal closure. The remaining patient had his patch removed and ultimately underwent skin grafting and subsequent component separation closure. Successful fascial closure was achieved after 15.5 days +/- 10.2 days (range, 5-42 days). The skin was left open in half of the patients. There were four abdominal complications that were noted while the patch was in place. Three of four complications were related to the primary disease, and in the fourth complication the patch became infected and had to be removed. There were no eviscerations or enterocutaneous fistulas after primary fascial closure. The median length of stay was 28 days (Interquartile range, 14-39 days).
CONCLUSIONS: Use of the Wittmann Patch can achieve a high rate of delayed fascial closure in severe trauma and critically ill emergency surgery patients with open abdomens. Most of the complications associated with use of the patch were wound infections after fascial closure and closure of the skin.

Entities:  

Mesh:

Year:  2008        PMID: 18849804     DOI: 10.1097/TA.0b013e31818481f1

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  20 in total

Review 1.  EHS clinical guidelines on the management of the abdominal wall in the context of the open or burst abdomen.

Authors:  M López-Cano; J M García-Alamino; S A Antoniou; D Bennet; U A Dietz; F Ferreira; R H Fortelny; P Hernandez-Granados; M Miserez; A Montgomery; S Morales-Conde; F Muysoms; J A Pereira; R Schwab; N Slater; A Vanlander; G H Van Ramshorst; F Berrevoet
Journal:  Hernia       Date:  2018-09-03       Impact factor: 4.739

2.  Reversibility of abdominal wall atrophy and fibrosis after primary or mesh herniorrhaphy.

Authors:  Eric J Culbertson; Liyu Xing; Yuan Wen; Michael G Franz
Journal:  Ann Surg       Date:  2013-01       Impact factor: 12.969

3.  Managing the open abdomen in a district general hospital.

Authors:  J De Siqueira; O Tawfiq; J Garner
Journal:  Ann R Coll Surg Engl       Date:  2014-04       Impact factor: 1.891

4.  Surgical strategies for management of the open abdomen.

Authors:  Justin L Regner; Leslie Kobayashi; Raul Coimbra
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

5.  Outcomes and complications of open abdomen technique for managing non-trauma patients.

Authors:  Kritaya Kritayakirana; Paul M Maggio; Susan Brundage; Mary-Anne Purtill; Kristan Staudenmayer; David A Spain
Journal:  J Emerg Trauma Shock       Date:  2010-04

Review 6.  Options for closure of the infected abdomen.

Authors:  Kristin C Turza; Chris A Campbell; Laura H Rosenberger; Amani D Politano; Stephen W Davies; Lin M Riccio; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2012-12-10       Impact factor: 2.150

7.  Chemical components separation with botulinum toxin A: a novel technique to improve primary fascial closure rates of the open abdomen.

Authors:  M D Zielinski; N Goussous; H J Schiller; D Jenkins
Journal:  Hernia       Date:  2012-09-22       Impact factor: 4.739

8.  Planned re-laparotomy and the need for optimization of physiology and immunology.

Authors:  L Kobayashi; R Coimbra
Journal:  Eur J Trauma Emerg Surg       Date:  2014-03-27       Impact factor: 3.693

9.  Management of Open Abdomen After Trauma Laparotomy: A Comparative Analysis of Dynamic Fascial Traction and Negative Pressure Wound Therapy Systems.

Authors:  Yifan Wang; Abdulaziz Alnumay; Tiffany Paradis; Andrew Beckett; Paola Fata; Kosar Khwaja; Tarek Razek; Jeremy Grushka; Dan L Deckelbaum
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

10.  Abdominal Decompression after Cardiac Surgery: Outcome of 42 Patients with Abdominal Compartment Syndrome.

Authors:  Michaela Ramser; Philippe M Glauser; Tracy R Glass; Benjamin Weixler; Martin T R Grapow; Henry Hoffmann; Philipp Kirchhoff
Journal:  World J Surg       Date:  2021-01-22       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.